End-stage renal disease: Why aren't improvements in hypertension treatment reducing the risk?

Edgar Jaimes, Josep Maria Galceran, Leopoldo Raij

Research output: Contribution to journalShort survey

8 Scopus citations

Abstract

Although we have seen a decreased incidence of some of the complications of hypertension, such as myocardial infarction and stroke, the same cannot be said for end-stage renal disease (ESRD). The disparity brings up the question of why improvements in hypertension control apparently do not bring improvement in the incidence of ESRD. Some of the factors likely at play include variation in the mechanisms at work in hypertensive patients of different races and variation in the degree to which antihypertensive agents affect systemic blood pressure and glomerular capillary pressure. These and other factors relating to hypertension and ESRD are the focus of this review.

Original languageEnglish (US)
Pages (from-to)471-476
Number of pages6
JournalCurrent opinion in cardiology
Volume11
Issue number5
DOIs
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'End-stage renal disease: Why aren't improvements in hypertension treatment reducing the risk?'. Together they form a unique fingerprint.

  • Cite this